Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders

Current Opinion in HIV and AIDS

Volumn 9, Issue 6, 2014, Pages 585-590

  Gendelman, Howard E ^a   Gelbard, Harris A ^b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

HIV associated neurocognitive disorders; Mixed lineage kinase; Nanoformulated antiretroviral therapy; Neuroinflammation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CEP 1347; LONG ACTING DRUG; MIXED LINEAGE KINASE; ANTIRETROVIRUS AGENT;

DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG FORMULATION; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNITY; INFLAMMATION; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL CLEARANCE; AIDS DEMENTIA COMPLEX; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; COGNITION DISORDERS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PATHOPHYSIOLOGY; PROCEDURES; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; HIV INFECTIONS; HIV-1; HUMANS; NANOMEDICINE;

EID: 84924257481     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000111     Document Type: Review

References (59)

1. Gelbard HA, Dewhurst S, Maggirwar SB, et al. Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase. Neurotherapeutics 2010; 7:392-398.
2. Blackstone K, Moore DJ, Heaton RK, et al. CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group. Diagnosing symptomatic HIVassociated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc 2012; 18:79-88.
3. Morley D, McNamara P, Kennelly S, et al. Limitations to the identification of HIV-associated neurocognitive disorders in clinical practice. HIV Med 2013; 14:497-502.
4. Heaton RK, Clifford DB, Franklin DR Jr, et al. CHARTER Group. HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
5. Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous systemtargeted antiretrovirals for HIV-associated neurocognitive disorder. Clinical Infect Dis 2014; 58:1015-1022.
6. Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014; 83:134-141.
7. Zhang G, Dash PK, Guo D et al. NanoART facilitated HIV-1 clearance by a mixed-lineage kinase 3 inhibitor. Conference on retroviruses and opportunistic infections; 3-6 March 2013; Boston, Massachusetts, USA; 2014.
8. Tan IL, McArthur JC. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 2012; 26:123-134.
9. Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 2002; 3:663-672.
10. Silva RM, Kuan CY, Rakic P, Burke RE. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov Disord 2005; 20:653-664.
11. Wang LH, Besirli CG, Johnson EM Jr. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 2004; 44:451-474.
12. Maroney AC, Finn JP, Connors TJ, et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001; 276:25302-25308.
13. Handley ME, Rasaiyaah J, Barnett J, et al. Expression and function of mixed lineage kinases in dendritic cells. Int Immunol 2007; 19:923-933.
14. Handley ME, Rasaiyaah J, Chain BM, Katz DR. Mixed lineage kinases (MLKs): a role in dendritic cells, inflammation and immunity? Int J Exp Pathol 2007; 88:111-126.
15. Jaeschke A, Davis RJ. Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 2007; 27:498-508.
16. Sathyanarayana P, Barthwal MK, Kundu CN, et al. Activation of the drosophila MLK by ceramide reveals TNF-alpha and ceramide as agonists of mammalian MLK3. Mol Cell 2002; 10:1527-1533.
17. Leung IW, Lassam N. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J Biol Chem 1998; 273:32408-32415.
18. Leung IW, Lassam N. The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J Biol Chem 2001; 276:1961-1967.
19. Sui Z, Fan S, Sniderhan L, et al. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol 2006; 177:702-711.
20. New DR, Maggirwar SB, Epstein LG, et al. HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaB-independent mechanism. J Biol Chem 1998; 273:17852-17858.
21. Dewhurst S, Maggirwar SB, Schifitto G, et al. Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol 2007; 2:93-96.
22. Mishra R, Barthwal MK, Sondarva G, et al. Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem 2007; 282:30393-30405.
23. Yin XH, Zhang QG, Miao B, Zhang GY. Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation. J Neurochem 2005; 93:1021-1029.
24. Barthwal MK, Sathyanarayana P, Kundu CN, et al. Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J Biol Chem 2003; 278:3897-3902.
25. Chadee DN, Xu D, Hung G, et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A 2006; 103:4463-4468.
26. Mota M, Reeder M, Chernoff J, Bazenet CE. Evidence for a role of mixed lineage kinases in neuronal apoptosis. J Neurosci 2001; 21:4949-4957.
27. Savinainen A, Garcia EP, Dorow D, et al. Kainate receptor activation induces mixed lineage kinase-mediated cellular signaling cascades via postsynaptic density protein. J Biol Chem 2001; 276:11382-11386.
28. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J Pharmacol Exp Ther 1999; 288:421-427.
29. Saporito MS, Hudkins RL, Maroney AC. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem 2002; 40:23-62.
30. Mathiasen JR, McKenna BA, Saporito MS, et al. Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells. Brain Res 2004; 1003:86-97.
31. Lotharius J, Falsig J, van Beek J, et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 2005; 25:6329-6342.
32. Barber SA, Uhrlaub JL, DeWitt JB, et al. Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am J Pathol 2004; 164:355-362.
33. Johnson GV, Bailey CD. The p38 MAP kinase signaling pathway in Alzheimer's disease. Exp Neurol 2003; 183:263-268.
34. Troy CM, Rabacchi SA, Xu Z, et al. beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001; 77:157-164.
35. Barone FC, Parsons AA. Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin Investig Drugs 2000; 9:2281-2306.
36. Hu WW, Du Y, Li C, et al. Neuroprotection of hypothermia against neuronal death in rat hippocampus through inhibiting the increased assembly of GluR6-PSD95-MLK3 signaling module induced by cerebral ischemia/reperfusion. Hippocampus 2008; 18:386-397.
37. Tian H, Zhang QG, Zhu GX, et al. Activation of c-Jun NH2-terminal kinase 3 is mediated by the GluR6.PSD-95.MLK3 signaling module following cerebral ischemia in rat hippocampus. Brain Res 2005; 1061:57-66.
38. Zhang QG, Wang RM, Yin XH, et al. Knock-down of POSH expression is neuroprotective through down-regulating activation of the MLK3-MKK4-JNK pathway following cerebral ischaemia in the rat hippocampal CA1 subfield. J Neurochem 2005; 95:784-795.
39. Zhang QG, Wang XT, Han D, et al. Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem 2006; 98:1886-1898.
40. Zhang QX, Pei DS, Guan QH, et al. Crosstalk between PSD-95 and JIP1-mediated signaling modules: the mechanism of MLK3 activation in cerebral ischemia. Biochemistry 2007; 46:4006-4016.
41. Liao S, Porter D, Scott A, et al. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. J Mol Cell Cardiol 2007; 42:106-120.
42. Bodner A, Maroney AC, Finn JP, et al. Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity. J Neurochem 2002; 82:1424-1434.
43. Bodner A, Toth PT, Miller RJ. Activation of c-Jun N-terminal kinase mediates gp120IIIB-and nucleoside analogue-induced sensory neuron toxicity. Exp Neurol 2004; 188:246-253.
44. Pirvola U, Xing-Qun L, Virkkala J, et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 2000; 20:43-50.
45. Sugahara K, Rubel EW, Cunningham LL. JNK signaling in neomycin-induced vestibular hair cell death. Hear Res 2006; 221:128-135.
46. Ylikoski J, Xing-Qun L, Virkkala J, Pirvola U. Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Hear Res 2002; 166:33-43.
47. Falsig J, Porzgen P, Lotharius J, Leist M. Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol 2004; 173:2762-2770.
48. Lund S, Porzgen P, Mortensen AL, et al. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J Neurochem 2005; 92:1439-1451.
49. Hehner SP, Hofmann TG, Ushmorov A, et al. Mixed-lineage kinase 3 delivers CD3/CD28-derived signals into the IkappaB kinase complex. Mol Cell Biol 2000; 20:2556-2568.
50. Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 2004; 62:330-332.
51. Wu SS, Frucht SJ. Treatment of Parkinson's disease: what's on the horizon? CNS Drugs 2005; 19:723-743.
52. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007; 69:1480-1490.
53. Dou H, Ellison B, Bradley J, et al. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 2005; 25:8375-8385.
54. Eggert D, Dash PK, Gorantla S, et al. Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol 2010; 184:746-756.
55. Brancho D, Ventura JJ, Jaeschke A, et al. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol Cell Biol 2005; 25:3670-3681.
56. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23:329-336.
57. Roux PP, Dorval G, Boudreau M, et al. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J Biol Chem 2002; 277:49473-49480.
58. Goodfellow VS, Loweth CJ, Ravula SB, et al. Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem 2013; 56:8032-8048.
59. Marker DF, Tremblay ME, Puccini JM, et al. The new small-molecule mixedlineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. J Neurosci 2013; 33:9998-10010.